Thus, by combining different epigenetic effector domains, such as DNMT3 and Tet1, with dCas9 [22, 36], therapeutic epigenetic editing acts as a promising therapeutic tool for various neurological diseases, including FXS, ALS, and PD, with minimal side effects. This evidence concerns the gene TET1 and fragile X syndrome.